Phillip Md Et Al Frost Buys 199,072 Shares of OPKO Health, Inc. (NASDAQ:OPK) Stock

OPKO Health, Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost purchased 199,072 shares of the firm’s stock in a transaction that occurred on Friday, November 29th. The shares were bought at an average cost of $1.53 per share, with a total value of $304,580.16. Following the completion of the acquisition, the chief executive officer now owns 211,911,477 shares of the company’s stock, valued at approximately $324,224,559.81. This trade represents a 0.09 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Phillip Md Et Al Frost also recently made the following trade(s):

• On Friday, November 22nd, Phillip Md Et Al Frost bought 100,000 shares of OPKO Health stock. The stock was purchased at an average price of $1.59 per share, with a total value of $159,000.00.
• On Thursday, November 14th, Phillip Md Et Al Frost purchased 100,000 shares of OPKO Health stock. The shares were purchased at an average price of $1.62 per share, for a total transaction of $162,000.00.
• On Friday, November 8th, Phillip Md Et Al Frost acquired 280,183 shares of OPKO Health stock. The stock was acquired at an average cost of $1.50 per share, for a total transaction of $420,274.50.

OPKO Health Stock Performance

Shares of OPK stock opened at $1.54 on Friday. The stock has a fifty day moving average price of $1.52 and a 200 day moving average price of $1.45. The company has a debt-to-equity ratio of 0.30, a quick ratio of 2.69 and a current ratio of 2.97. The stock has a market cap of $1.05 billion, a PE ratio of -8.11 and a beta of 1.65. OPKO Health, Inc. has a 1 year low of $0.85 and a 1 year high of $1.75.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Rubric Capital Management LP increased its holdings in OPKO Health by 800.0% during the 2nd quarter. Rubric Capital Management LP now owns 44,422,304 shares of the biotechnology company’s stock valued at $55,528,000 after acquiring an additional 39,486,490 shares in the last quarter. Y.D. More Investments Ltd acquired a new stake in shares of OPKO Health in the second quarter valued at approximately $1,840,000. Assenagon Asset Management S.A. grew its position in shares of OPKO Health by 142.5% in the third quarter. Assenagon Asset Management S.A. now owns 1,490,992 shares of the biotechnology company’s stock valued at $2,227,000 after purchasing an additional 876,272 shares during the last quarter. Clearline Capital LP purchased a new position in shares of OPKO Health during the 3rd quarter worth approximately $1,083,000. Finally, Squarepoint Ops LLC acquired a new position in shares of OPKO Health during the 2nd quarter worth approximately $592,000. Institutional investors and hedge funds own 64.63% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on the company. Barrington Research reissued an “outperform” rating and set a $2.25 target price on shares of OPKO Health in a research note on Friday, November 8th. HC Wainwright reissued a “buy” rating and issued a $3.00 target price on shares of OPKO Health in a report on Thursday, September 26th. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $3.00 price target on shares of OPKO Health in a research note on Tuesday, September 17th.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.